Paralysis Research Funding & Clinical Trial Possibilities:

1.  Acorda Therapeutics is in preclinical development/research regarding the enzyme, chondroitinase for central nervous system (CNS) repair. This needs to be further researched in the Denver Metro area, which has a large number of MS and paralysis patients.  We need medical doctors from Children's Hospital, Swedish Hospital, CU Boulder and CU Denver to host a consortium of Acorda Therapeutics experts.

2.  Pfaff Laboratory is furthering the identification and mapping of neurons with genetic markers. We need Pfaff Laboratory to be hosted at a consortium in Denver.

3.  Astrocytes and astrocyte-secreting molecules may possibly lead to breakthrough treatments. This may be a possible clinical trial in the future.

4.  Inhibiting inflammation by studying microglia may also help prevent further damage to the CNS, and lead to repairing it. Microglia research needs funding in Denver too. We need the finest international researchers from the country to further study microglia.

5.  Novartis has researched anti-NogoA (or NogoA-inhibitors) to repair the CNS and there might be future possibilities that our paralyzed veterans could be included in clinical trials for anti-NogoA treatments and medications. We need to lobby for them to be included in the development of anti-NogoA medical treatments. Also, we need to hire Novartis medical researchers in Denver, in order to train our local, privatized and veterans' healthcare medical researchers.

6.  Oligodendrocyte precursor (myelin sheath repairing) research may also assist our MS and paralysis victims in Denver. We need to fundraise and submit federal fund requests so we can get clinical trials underway as soon as possible. We need the best bioengineered mice for our local medical researchers. Denver and Boulder could get pharmaceutical clinical trials/drug patent funds, groundbreaking treatments and job opportunities if we participate in genetic research of these oligodendrocyte precursors.